3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Patients With Pneumonia: A Prospective Observational Study

      research-article
      , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
      Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
      Oxford University Press
      immunocompromised pneumonia, bronchoscopy, hematologic malignancy, hematopoietic cell transplant, microbial cell-free DNA sequencing

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Pneumonia is a common cause of morbidity and mortality, yet a causative pathogen is identified in a minority of cases. Plasma microbial cell-free DNA sequencing may improve diagnostic yield in immunocompromised patients with pneumonia.

          Methods

          In this prospective, multicenter, observational study of immunocompromised adults undergoing bronchoscopy to establish a pneumonia etiology, plasma microbial cell-free DNA sequencing was compared to standardized usual care testing. Pneumonia etiology was adjudicated by a blinded independent committee. The primary outcome, additive diagnostic value, was assessed in the Per Protocol population (patients with complete testing results and no major protocol deviations) and defined as the percent of patients with an etiology of pneumonia exclusively identified by plasma microbial cell-free DNA sequencing. Clinical additive diagnostic value was assessed in the Per Protocol subgroup with negative usual care testing.

          Results

          Of 257 patients, 173 met Per Protocol criteria. A pneumonia etiology was identified by usual care in 52/173 (30.1%), plasma microbial cell-free DNA sequencing in 49/173 (28.3%) and the combination of both in 73/173 (42.2%) patients. Plasma microbial cell-free DNA sequencing exclusively identified an etiology of pneumonia in 21/173 patients (additive diagnostic value 12.1%, 95% confidence interval [CI], 7.7% to 18.0%, P < .001). In the Per Protocol subgroup with negative usual care testing, plasma microbial cell-free DNA sequencing identified a pneumonia etiology in 21/121 patients (clinical additive diagnostic value 17.4%, 95% CI, 11.1% to 25.3%).

          Conclusions

          Non-invasive plasma microbial cell-free DNA sequencing significantly increased diagnostic yield in immunocompromised patients with pneumonia undergoing bronchoscopy and extensive microbiologic and molecular testing.

          Clinical Trials Registration

          NCT04047719.

          Abstract

          In this prospective multicenter observational study of immunocompromised patients undergoing bronchoscopy, plasma microbial cell-free DNA sequencing exclusively identified an adjudicated pneumonia etiology in 12.1% of patients with otherwise nondiagnostic testing, significantly increasing overall diagnostic yield in this high-risk population.

          Graphical Abstract

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

          Invasive fungal diseases are important causes of morbidity and mortality. Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies. After the introduction of the original European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition of areas in need of improvement led to a revision of this document. The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved. The revised definitions retain the original classifications of "proven," "probable," and "possible" invasive fungal disease, but the definition of "probable" has been expanded, whereas the scope of the category "possible" has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for immunocompromised patients only. These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation.

              Pulmonary infiltrates frequently complicate hematopoietic SCT (HSCT). The utility of fiberoptic bronchoscopy (FOB) with bronchoalveolar lavage (BAL) in the evaluation of new pulmonary infiltrates, particularly as it relates to optimal timing of the procedure, is unclear. Based on this, we retrospectively reviewed 501 consecutive, adult, nonintubated patients who underwent 598 BALs for evaluation of new pulmonary infiltrates during the first 100 days following HSCT to determine whether diagnostic yields for infection, subsequent antimicrobial treatment modifications and patient outcomes differed following early vs late referrals for the procedure. The overall yield of BAL for clinically significant pathogens was 55%. Notably, the yield was 2.5-fold higher among FOBs performed within the first 4 days of presentation (early FOB) compared to those performed late, and highest (75%) when performed within 24 h of clinical presentation. Rates of FOB-guided adjustments in antimicrobial therapy (51%) did not differ significantly between early and late examinations. However, late FOB-related antibiotic adjustments were associated with 30-day pulmonary-associated deaths that were threefold higher (6 vs 18%, P=0.0351). Major FOB-related complications occurred in only three (0.6%) patients. We conclude that early referral for FOB in this patient setting is associated with higher diagnostic yields and may favorably impact survival.
                Bookmark

                Author and article information

                Contributors
                Journal
                Clin Infect Dis
                Clin Infect Dis
                cid
                Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
                Oxford University Press (US )
                1058-4838
                1537-6591
                15 March 2024
                10 October 2023
                10 October 2023
                : 78
                : 3
                : 775-784
                Affiliations
                Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine , Durham, North Carolina, USA
                Duke Clinical Research Institute , Durham, North Carolina, USA
                Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas, USA
                Department of Medicine, Division of Infectious Diseases, City of Hope National Medical Center , Duarte California, California, USA
                Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington, USA
                Department of Medicine, University of Washington School of Medicine , Seattle, Washington, USA
                Infectious Diseases Service, Memorial Sloan Kettering Cancer Center , NewYork, New York, USA
                Department of Medicine, Weill Cornell Medicine , NewYork, New York, USA
                Department of Medicine, Division of Infectious Diseases, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania, USA
                Section of Infectious Diseases, John W. Deming Department of Medicine, Tulane University School of Medicine , New Orleans, Louisiana, USA
                Department of Medicine, Weill Cornell Medicine , NewYork, New York, USA
                Department of Medicine, NewYork-Presbyterian Hospital , New York, New York, USA
                Division of Infectious Diseases, University of California San Francisco , San Francisco, California, USA
                Division of Infectious Diseases, University of Colorado , Aurora, Colorado, USA
                Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center , Houston, Texas, USA
                Department of Medicine, Division of Infectious Diseases, City of Hope National Medical Center , Duarte California, California, USA
                Infectious Diseases Service, Memorial Sloan Kettering Cancer Center , NewYork, New York, USA
                Department of Medicine, Weill Cornell Medicine , NewYork, New York, USA
                Department of Medicine, Weill Cornell Medicine , NewYork, New York, USA
                Department of Medicine, NewYork-Presbyterian Hospital , New York, New York, USA
                Division of Infectious Diseases, University of California San Francisco , San Francisco, California, USA
                Division of Infectious Diseases, University of Colorado , Aurora, Colorado, USA
                Department of Pathology and Laboratory Medicine, Indiana University School of Medicine , Indianapolis, Indiana, USA
                Duke Clinical Research Institute , Durham, North Carolina, USA
                Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine , Durham, North Carolina, USA
                Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine , Durham, North Carolina, USA
                Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine , Durham, North Carolina, USA
                Duke Clinical Research Institute , Durham, North Carolina, USA
                Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University School of Medicine , Durham, North Carolina, USA
                Duke Clinical Research Institute , Durham, North Carolina, USA
                Duke Clinical Research Institute , Durham, North Carolina, USA
                Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Emergency Medicine Services, Durham Veterans Affairs Health Care System , Durham, North Carolina, USA
                VP and Chief Scientific Officer, Infectious Disease, Danaher Diagnostics , Washington, DC, USA
                Duke Clinical Research Institute , Durham, North Carolina, USA
                Karius Inc. , Redwood City, California, USA
                Karius Inc. , Redwood City, California, USA
                Karius Inc. , Redwood City, California, USA
                Karius Inc. , Redwood City, California, USA
                Karius Inc. , Redwood City, California, USA
                Karius Inc. , Redwood City, California, USA
                Karius Inc. , Redwood City, California, USA
                Duke Clinical Research Institute , Durham, North Carolina, USA
                Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Duke Clinical Research Institute , Durham, North Carolina, USA
                Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine , Durham, North Carolina, USA
                Author notes
                Correspondence: T. L. Holland, Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, DUMC 102359, Durham, NC 27710 ( thomas.holland@ 123456duke.edu ).
                Correspondence: S. P. Bergin, Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University Medical Center, DUMC 2629, Durham, NC 27710 ( stephen.bergin@ 123456duke.edu ).

                Potential conflicts of interest. S. P. B. reports being a consultant to C3J Therapeutics. R. F. C. reports being a scientific advisor or consultant for ADMA Biologics, Pulmotec, Janssen, Merck/MSD, Partner Therapeutics, Takeda, Shinoigi, Genentech, Astellas, Adagio Therapeutics, Oxford Immunotec, Qiagen, Karius, and Ansun Pharmaceuticals and received research grants paid to his institution from National Institutes of Health (NIH)/National Cancer Institute (NCI), Merck/Merck, Sharp & Dohme (MSD), Karius, AiCuris, Ansun Pharmaceuticals, Takeda, Genentech, Oxford Immunotec, Freestyle, and Eurofins-Viracor, and reports payment or honoraria as a speaker for Qiagen and Viracor-Eurofins. S. D. reports research grants paid to his institution from Karius, Merck, Gilead, Ansun Biopharma, Allovir, Geovax. He has served on advisory boards of Merck, Takeda, Allovir, and Aseptiscope, Inc. He is on speaker's bureau of Merck, Astellas and Takeda, and reports payment or honoraria from Viracor for educational event at ID week 2022 and from MJH for cytomegalovirus (CMV) symposium at American Society of Hematology (ASH) 2022. He has stock options in Aseptiscope, Inc, Matinas Biopharma, and Cidara Therapeutics. He reports consulting fees from Merck and Allovir; support for attending meetings and/or travel from American Society of Transplantation and Cellular Therapy—Tandem 2022 and 2023 (registration credit), ID week 2022—Infectious Diseases Society of America (IDSA) (partial support—airfare), and Immunocompromised Host Society (ICHS) 2022 (air fare and hotel expenses); Patent # 9416395, Assigned to City of Hope. Inventors—Markus Kalkum, Karine Bagramyan, Diana Diaz-Arevalo, James I. Ito, Sanjeet S. Dadwal (assigned to City of Hope) and US Provisional Patent Application no. 63/067,855: Inventors—Markus Kalkum, Daniel Roeth, Sanjeet S. Dadwal (assigned to City of Hope); a role as Chair of Transplant Infectious Disease Special Interest Group of American Society of Transplant and Cellular Therapy (ASTCT). J. A. H. reports research grants paid to his institution from Karius and consulting for Karius and support for travel to advisory board meeting from Karius. Y. J. L. has served as an investigator for Astellas, Karius, AiCuris, and Scynexis and has received research grant support from Merck & Co Inc. G. H. is a recipient of research grants from Allovir, Karius, and AstraZeneca and also serves on the scientific advisory boards of and receives consulting fees from Karius and AstraZeneca, and reports grants or contracts from NIH; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from MDOutlook, PeerView Medical Education, International AIDS Society. A. L. reports consulting fees from Karius. F. K. reports honorarium from Medscape and research support from Eurofins-Viracor. G. A. P. reports research support from MSD and Takeda/Shire and consulting and other fees from AlloVir, Amplyx, SLC Behring, Cidara, MSD, Takeda and Octapharma. C. B. S. reports research grant support from NIH, GlaxoSmithKline, ViiV, Abbott, Merck, Gilead, Chimerix, Shire/Takeda, Schering-Plough, Ablynx, Janssen, Ansun Biopharma, and Karyopharm Therapeutics; participation on Janssen Respiratory Viruses Advisory Board and Merck Scientific Input Engagement (SIE) Panel for Molnupirivir. M. F. reports research grant support from NIH, and research funding (UCSF PI Fung) from Scynexis and Vatic, Ltd. M. T. M. reports being a consultant for UpToDate and Karius and a co-inventor of patents on Methods to Detect and Treat Acute Respiratory Infections. E. K. M. reports consulting fees from Karius Inc as a Clinical Events Committee member/reviewer—received payments as clinical adjudicator for another Karius project. D. B. M. reports consulting fees from Karius Inc.. A. D. B . reports payment or honoraria from Novartis for lecture on Sepsis Watch, AI program developed at Duke. J. L. T. reports advisory board participation for Sanofi, Natera, Theravance and Altavant Sciences (now Enzyvant Therapeutics) in addition to grants to the institution from Boehringer-Ingelheim, AstraZeneca, Sanofi, NIH, Cystic Fibrosis Foundation and CareDx; and consulting fees from Sanofi. C. E. B. reports grants or contracts from American Lung Association and NIH (National Heart, Lung, and Blood Institute [NHLBI] and National Institute of Allergy and Infectious Diseases [NIAID] funded projects—not related to this project); participation as member of a Data and Safety Monitoring Board (DSMB) for VASSPR—an ICU-based trial with no relationship to this project. R. B. reports stock holdings in Merck, Johnson & Johnson, COVIDien, Pfizer, Sanofi, McKesson, and Viatris and consulting fees from Elixir. E. L. T. reports personal fees from Biomeme and Predigen, stock options in Danaher, and being an employee of Danaher Corp. O, W. reports support for attending meetings and/or travel from Karius (as Clinical Events Classification [CEC] Project Leader initiated and attended meetings with Karius for the PICKUP study); a role as CEC Project Leader coordinated CEC committee meetings within Duke Clinical Research Institute (DCRI) for the PICKUP trial. M. M. reports being an employee of Karius Inc, Redwood City, California, and may own stock options. D. H. reports being a former employee of Karius Inc, Redwood City, California, and a patent issued for related work while at Karius as employee (WO-2020106987-A1—Detection and Prediction of Infectious Disease). R. D. reports being a former employee of Karius Inc, Redwood City, California, and is owner of Karius stock options. D. S. L. reports being an employee of Karius Inc, Redwood City, California, and may own stock options. S. B. reports being an employee of Karius Inc, Redwood City, California, and may own stock options, and reports support for attending meetings and/or travel and patents planned, issued, or pending with Karius Inc. B, A. P. reports being an employee of Karius Inc, Redwood City, California, patents planned, issued or pending with Karius Inc, and may own stock options. T. A. B. reports being an employee of and having a leadership or fiduciary role with Karius Inc, Redwood City, California, and may own stock options. V. G. F. reports personal fees from Novartis, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., MedImmune, Bayer, Basilea, Affinergy, Janssen, Contrafect, Regeneron, Destiny, Amphliphi Biosciences, Integrated Biotherapeutics; C3J, Armata, Valanbio; Akagera, Aridis, Roche, grants from NIH, MedImmune, Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius; Genentech, Regeneron, Deep Blue, Basilea, Janssen; royalties from UpToDate, stock options from Valanbio and ArcBio, honoraria from IDSA for his service as Associate Editor of Clinical Infectious Diseases, and a patent sepsis diagnostics pending. T. L. H. reports being an advisor and consultant to Aridis, Basilea Pharmaceutica, Karius, and Lysovant; royalties from UpToDate; reports grants or contracts with Karius (adjudication committee) and with NIH; reports consulting fees from Pfizer and Affinivax; participation on DSMB for platform trial for SNAP Trial; and on advisory board for Basilea. All other authors report no potential conflicts.

                All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

                Author information
                https://orcid.org/0000-0001-7745-9010
                Article
                ciad599
                10.1093/cid/ciad599
                10954333
                37815489
                c106cc23-1eb0-4111-a9b5-d90e01aa669d
                © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 30 June 2023
                : 02 August 2023
                : 04 November 2023
                Page count
                Pages: 10
                Funding
                Funded by: Karius Inc;
                Funded by: Duke Clinical Research Institute, DOI 10.13039/100006513;
                Categories
                Major Article
                Respiratory Infections
                AcademicSubjects/MED00290
                Editor's Choice

                Infectious disease & Microbiology
                immunocompromised pneumonia,bronchoscopy,hematologic malignancy,hematopoietic cell transplant,microbial cell-free dna sequencing

                Comments

                Comment on this article